http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111297898-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
| filingDate | 2020-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111297898-B |
| titleOfInvention | Application of extracellular vesicles derived from mesenchymal stem cells in cerebral ischemia-reperfusion injury |
| abstract | The invention provides application of extracellular vesicles derived from mesenchymal stem cells in cerebral ischemia reperfusion injury. The research of the invention finds and confirms that extracellular vesicles (MSCs-EVs) derived from mesenchymal stem cells can treat brain dysfunction and have neuroprotective effect through neurogenesis and angiogenesis after stroke. Research results show that the MSCs-EVs can obviously relieve 24h and 48h of neurological deficit after MCAO of rats, reduce the volume of cerebral infarction and the brain water content, improve pathological damage of cerebral tissue cortex, weaken apoptosis of cortical neurons and obviously up-regulate p-AMPK, and down-regulate p-JAK2, p-STAT3 and p-NF-kappa B. The present invention provides the necessary support for the use of MSCs-EVs as a potential therapeutic strategy for MCAO treatment. |
| priorityDate | 2020-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 124.